Late Preterm Corticosteroids and Neonatal Hypoglycemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-31

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective randomized controlled trial investigating the timing of betamethasone administration in late preterm infants in relation to delivery and impact on neonatal hypoglycemia. Previous data has shown that neonatal hypoglycemia is increased in late preterm infants that were exposed to antenatal corticosteroids. The investigators hypothesize that the timing of steroid administration may impact the development of neonatal hypoglycemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants

NCT01206946

Respiratory Distress Syndrome, Newborn Transient Tachypnea of the Newborn

UNKNOWN PHASE2

Neurodevelopment of Hypoglycemic Neonates

NCT04875624

Neonatal Hypoglycemia Neurodevelopmental Disorders

COMPLETED

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

NCT01222247

Pregnancy Respiratory Distress Syndrome Pregnancy Outcomes +1 more

COMPLETED PHASE3

Antenatal Corticoid Therapy for Late Preterm Babies

NCT00675246

Hyaline Membrane Disease Transient Tachypnea

COMPLETED NA

Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants

NCT00358748

Neonatal Hypotension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The use of antenatal corticosteroids for women at risk for preterm delivery has become widely adopted as standard of care. The American College of Obstetrics and Gynecologists (ACOG) officially recommends the use of corticosteroids for pregnant women between 24 and 34 weeks of gestation at risk of delivery within 7 days. Since publication of the ALPS trial, the Society of Maternal Fetal Medicine (SMFM) published guidelines supporting the use of late preterm steroids for singleton pregnancies between 34 weeks 0 days and 36 weeks 6 days who are at high risk of preterm birth within 7 days.

A secondary finding of the ALPS trial included the observation that the administration of antenatal betamethasone significantly increased the rate of neonatal hypoglycemia; the authors emphasized that while the long-term risks associated with neonatal hypoglycemia are not fully known, significant hypoglycemia is associated with poor neurodevelopmental outcome.

The optimal interval for administering late preterm steroids before delivery to minimize the risks of hypoglycemia while maximizing the benefits of fetal lung maturity has not been identified. The proposed research study will further investigate this question by randomizing patients to receive late preterm corticosteroids 2 days before delivery versus 7 days before delivery in order to determine if the rates and severity of neonatal hypoglycemia are different.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neonatal Hypoglycemia Prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Late Preterm Steroids 2 Days

Group Type ACTIVE_COMPARATOR

Betamethasone Sodium Phosphate

Intervention Type DRUG

Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses

Late Preterm Steroids 7 Days

Group Type ACTIVE_COMPARATOR

Betamethasone Sodium Phosphate

Intervention Type DRUG

Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Betamethasone Sodium Phosphate

Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Celestone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton pregnancy
* Gestational age 34 0/7 weeks to 36 5/7 weeks
* Planned delivery in late preterm period

Exclusion Criteria

* Prior course of betamethasone during pregnancy
* Twin gestation
* Fetal demise
* Major fetal anomaly
* Maternal contraindication to betamethasone
* Pregestational diabetes
* Expected delivery within 12 hours of randomization

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes